Please enable JavaScript to continue using this application.

Compare tickers

Valuation, margins, and growth side by side.

Compare $LGND vs $MANE | Chartloom

Compare

$LGND vs $MANE

Ligand Pharmaceuticals Inc · Veradermics Inc

LGND

Ligand Pharmaceuticals Inc

MANE

Veradermics Inc

Compare $LGND vs $MANE

Comparing Ligand Pharmaceuticals Inc and Veradermics Inc

LGNDLigand Pharmaceuticals Inc

MANEVeradermics Inc

LGNDLigand Pharmaceuticals Inc

Market cap

$6.08B

P/E (TTM)

33.61x

Forward P/E (NTM)

28.81x

Forward P/S (NTM)

17.73x

Rev growth (TTM)

54.9%

YTD performance

59.7%

52W performance

70.8%

FCF yield

2.2%

MANEVeradermics Inc

Market cap

$4.86B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

208.0%

52W performance

208.0%

FCF yield

-2.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

LGND

MANE

Detailed metrics comparison

LGND

Ligand Pharmaceuticals Inc

MANE

Veradermics Inc

Market Cap

LGND$6.08B

MANE$4.86B

Enterprise Value

LGND$6.20B

MANE$4.54B

Price

LGND$303.53

MANE$116.26

P/E Ratio

LGND33.61x

MANEN/A

P/S Ratio

LGND20.94x

MANE0.00x

EV/Sales

LGND21.35x

MANE0.00x

EV/EBITDA

LGND42.81x

MANE0.00x

P/B Ratio

LGND6.22x

MANE6.72x

P/FCF Ratio

LGND45.31x

MANEN/A

EV/FCF

LGND46.20x

MANE-42.29x

PEG Ratio

LGND1.33x

MANEN/A

Forward P/E (NTM)

LGND28.81x

MANEN/A

Forward P/S (NTM)

LGND17.73x

MANEN/A

Revenue (TTM)

LGND$291M

MANE$0

Revenue Growth (YoY)

LGND54.9%

MANEN/A

Forward Rev Growth

LGND31.3%

MANE308.7%

Gross Margin (TTM)

LGND95.4%

MANE0.0%

Operating Margin (TTM)

LGND32.6%

MANE0.0%

EBITDA Margin (TTM)

LGND45.8%

MANE0.0%

Net Margin (TTM)

LGND67.9%

MANE0.0%

FCF Margin (TTM)

LGND46.2%

MANEN/A

Net Income (TTM)

LGND$197M

MANE$-137M

FCF (TTM)

LGND$134M

MANE$-107M

EPS (TTM)

LGND$9.03

MANE-$3.39

ROE (TTM)

LGND20.1%

MANE-3549.0%

ROA (TTM)

LGND11.7%

MANE-3463.0%

ROIC (TTM)

LGND12.3%

MANE-3549.0%

Cash

LGND$1.01B

MANE$319M

Debt

LGND$1.13B

MANE$0

Net Cash/Debt

LGND$-120M

MANE$319M

Current Ratio (TTM)

LGND31.18x

MANE70.53x

Quick Ratio (TTM)

LGND30.96x

MANE70.35x

Debt/Equity (TTM)

LGND1.16x

MANE0.00x

Debt/Assets (TTM)

LGND0.0%

MANE0.0%

Interest Coverage (TTM)

LGNDN/A

MANEN/A

Net Debt/EBITDA (TTM)

LGND0.00x

MANE0.00x

Beta

LGND1.23

MANE-0.05

52W Performance

LGND70.8%

MANE208.0%

YTD Performance

LGND59.7%

MANE208.0%

% from 52W High

LGND-7.1%

MANE-15.0%

% from 52W Low

LGND72.6%

MANE263.3%

Asset Turnover (TTM)

LGND0.17x

MANE0.00x

FCF Yield (TTM)

LGND2.2%

MANE-2.2%

Earnings Yield (TTM)

LGND3.2%

MANE-2.8%

Dividend Yield (TTM)

LGNDN/A

MANEN/A

Rule of 40

LGND101.1

MANE0.0

EV/GP/RG

LGND1.14

MANEN/A

Ticker research

View LGND research View MANE research

Metric	LGND Ligand Pharmaceuticals Inc	MANE Veradermics Inc
Market & Valuation
Market Cap	$6.08B	$4.86B
Enterprise Value	$6.20B	$4.54B
Price	$303.53	$116.26
P/E Ratio	33.61x	N/A
P/S Ratio	20.94x	0.00x
EV/Sales	21.35x	0.00x
EV/EBITDA	42.81x	0.00x
P/B Ratio	6.22x	6.72x
P/FCF Ratio	45.31x	N/A
EV/FCF	46.20x	-42.29x
PEG Ratio	1.33x	N/A
Forward P/E (NTM)	28.81x	N/A
Forward P/S (NTM)	17.73x	N/A
Revenue & Growth
Revenue (TTM)	$291M	$0
Revenue Growth (YoY)	54.9%	N/A
Forward Rev Growth	31.3%	308.7%
Profitability
Gross Margin (TTM)	95.4%	0.0%
Operating Margin (TTM)	32.6%	0.0%
EBITDA Margin (TTM)	45.8%	0.0%
Net Margin (TTM)	67.9%	0.0%
FCF Margin (TTM)	46.2%	N/A
Net Income (TTM)	$197M	$-137M
FCF (TTM)	$134M	$-107M
EPS (TTM)	$9.03	-$3.39
ROE (TTM)	20.1%	-3549.0%
ROA (TTM)	11.7%	-3463.0%
ROIC (TTM)	12.3%	-3549.0%
Financial Health
Cash	$1.01B	$319M
Debt	$1.13B	$0
Net Cash/Debt	$-120M	$319M
Current Ratio (TTM)	31.18x	70.53x
Quick Ratio (TTM)	30.96x	70.35x
Debt/Equity (TTM)	1.16x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.23	-0.05
52W Performance	70.8%	208.0%
YTD Performance	59.7%	208.0%
% from 52W High	-7.1%	-15.0%
% from 52W Low	72.6%	263.3%
Efficiency & Yields
Asset Turnover (TTM)	0.17x	0.00x
FCF Yield (TTM)	2.2%	-2.2%
Earnings Yield (TTM)	3.2%	-2.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	101.1	0.0
EV/GP/RG	1.14	N/A
Ticker research	View LGND research	View MANE research

Valuation

P/E Ratio

LGND

33.61x

P/S Ratio

MANE

0.00x

LGND

20.94x

EV/FCF

MANE

-42.29x

LGND

46.20x

Growth & revenue

Revenue Growth TTM

LGND

54.9%

Forward Revenue Growth

MANE

308.7%

LGND

31.3%

Profitability & performance

Gross Margin

LGND

95.4%

MANE

0.0%

ROE

LGND

20.1%

MANE

-3549.0%

FCF Yield %

LGND

2.2%

MANE

-2.2%

52-Week Performance

MANE

208.0%

LGND

70.8%

Detailed metrics comparison

LGND

Ligand Pharmaceuticals Inc

MANE

Veradermics Inc

Market Cap

LGND$6.08B

MANE$4.86B

Enterprise Value

LGND$6.20B

MANE$4.54B

Price

LGND$303.53

MANE$116.26

P/E Ratio

LGND33.61x

MANEN/A

P/S Ratio

LGND20.94x

MANE0.00x

EV/Sales

LGND21.35x

MANE0.00x

EV/EBITDA

LGND42.81x

MANE0.00x

P/B Ratio

LGND6.22x

MANE6.72x

P/FCF Ratio

LGND45.31x

MANEN/A

EV/FCF

LGND46.20x

MANE-42.29x

PEG Ratio

LGND1.33x

MANEN/A

Forward P/E (NTM)

LGND28.81x

MANEN/A

Forward P/S (NTM)

LGND17.73x

MANEN/A

Revenue (TTM)

LGND$291M

MANE$0

Revenue Growth (YoY)

LGND54.9%

MANEN/A

Forward Rev Growth

LGND31.3%

MANE308.7%

Gross Margin (TTM)

LGND95.4%

MANE0.0%

Operating Margin (TTM)

LGND32.6%

MANE0.0%

EBITDA Margin (TTM)

LGND45.8%

MANE0.0%

Net Margin (TTM)

LGND67.9%

MANE0.0%

FCF Margin (TTM)

LGND46.2%

MANEN/A

Net Income (TTM)

LGND$197M

MANE$-137M

FCF (TTM)

LGND$134M

MANE$-107M

EPS (TTM)

LGND$9.03

MANE-$3.39

ROE (TTM)

LGND20.1%

MANE-3549.0%

ROA (TTM)

LGND11.7%

MANE-3463.0%

ROIC (TTM)

LGND12.3%

MANE-3549.0%

Cash

LGND$1.01B

MANE$319M

Debt

LGND$1.13B

MANE$0

Net Cash/Debt

LGND$-120M

MANE$319M

Current Ratio (TTM)

LGND31.18x

MANE70.53x

Quick Ratio (TTM)

LGND30.96x

MANE70.35x

Debt/Equity (TTM)

LGND1.16x

MANE0.00x

Debt/Assets (TTM)

LGND0.0%

MANE0.0%

Interest Coverage (TTM)

LGNDN/A

MANEN/A

Net Debt/EBITDA (TTM)

LGND0.00x

MANE0.00x

Beta

LGND1.23

MANE-0.05

52W Performance

LGND70.8%

MANE208.0%

YTD Performance

LGND59.7%

MANE208.0%

% from 52W High

LGND-7.1%

MANE-15.0%

% from 52W Low

LGND72.6%

MANE263.3%

Asset Turnover (TTM)

LGND0.17x

MANE0.00x

FCF Yield (TTM)

LGND2.2%

MANE-2.2%

Earnings Yield (TTM)

LGND3.2%

MANE-2.8%

Dividend Yield (TTM)

LGNDN/A

MANEN/A

Rule of 40

LGND101.1

MANE0.0

EV/GP/RG

LGND1.14

MANEN/A

Ticker research

View LGND research View MANE research

Metric	LGND Ligand Pharmaceuticals Inc	MANE Veradermics Inc
Market & Valuation
Market Cap	$6.08B	$4.86B
Enterprise Value	$6.20B	$4.54B
Price	$303.53	$116.26
P/E Ratio	33.61x	N/A
P/S Ratio	20.94x	0.00x
EV/Sales	21.35x	0.00x
EV/EBITDA	42.81x	0.00x
P/B Ratio	6.22x	6.72x
P/FCF Ratio	45.31x	N/A
EV/FCF	46.20x	-42.29x
PEG Ratio	1.33x	N/A
Forward P/E (NTM)	28.81x	N/A
Forward P/S (NTM)	17.73x	N/A
Revenue & Growth
Revenue (TTM)	$291M	$0
Revenue Growth (YoY)	54.9%	N/A
Forward Rev Growth	31.3%	308.7%
Profitability
Gross Margin (TTM)	95.4%	0.0%
Operating Margin (TTM)	32.6%	0.0%
EBITDA Margin (TTM)	45.8%	0.0%
Net Margin (TTM)	67.9%	0.0%
FCF Margin (TTM)	46.2%	N/A
Net Income (TTM)	$197M	$-137M
FCF (TTM)	$134M	$-107M
EPS (TTM)	$9.03	-$3.39
ROE (TTM)	20.1%	-3549.0%
ROA (TTM)	11.7%	-3463.0%
ROIC (TTM)	12.3%	-3549.0%
Financial Health
Cash	$1.01B	$319M
Debt	$1.13B	$0
Net Cash/Debt	$-120M	$319M
Current Ratio (TTM)	31.18x	70.53x
Quick Ratio (TTM)	30.96x	70.35x
Debt/Equity (TTM)	1.16x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.23	-0.05
52W Performance	70.8%	208.0%
YTD Performance	59.7%	208.0%
% from 52W High	-7.1%	-15.0%
% from 52W Low	72.6%	263.3%
Efficiency & Yields
Asset Turnover (TTM)	0.17x	0.00x
FCF Yield (TTM)	2.2%	-2.2%
Earnings Yield (TTM)	3.2%	-2.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	101.1	0.0
EV/GP/RG	1.14	N/A
Ticker research	View LGND research	View MANE research